Skip to main content
2024 Guide to Patient Support Services

Puma Biotechnology

2024 PSS Guide

Puma Biotechnology Support Services

Puma Patient Lynx
Puma Patient Lynx Enroll
Nerlynx Co-Pay Savings Program

Puma Biotechnology offers Puma Patient Lynx to assist patients while taking Nerlynx (Table).

Puma Patient Lynx Program

In addition to benefit verification, prior authorization assistance, and support for patients with financial needs, the Puma Patient Lynx program offers the following access and reimbursement services:

  • Nerlynx Quick Start provides a free 3-week supply of Nerlynx to eligible patients experiencing delays in accessing Nerlynx therapy
  • Nerlynx Co-Pay Savings Program is available for eligible, commercially insured patients (see below for details).

The Puma Patient Lynx program also offers the following ongoing treatment support services:

  • Nerlynx Mentor Program provides patient mentors to other patients who are considering or currently taking Nerlynx
  • Nurse Call Center is available for patients and healthcare providers to answer questions about Nerlynx. Nurses are available Monday to Friday from 9 am to 8 pm ET at 855-816-5421. Bilingual nurses are available
  • Text Message Support Program is available for patients who would like to receive medication reminders and motivational text messages

To learn more or to enroll your patient in Puma Patient Lynx, call 855-816-5421 or visit Puma Patient Lynx Enroll.

Nerlynx Co-Pay Savings Program

Puma Biotechnology offers co-pay assistance to help patients with out-of-pocket costs associated with their prescription.

To learn more or to enroll your patient in the Nerlynx Co-Pay Savings Program, call 855-816-5421 or visit Nerlynx Co-Pay Savings Program.

TABLE Puma Biotechnology Oncology Drug

Patient support programs

Nerlynx (neratinib) tablets
Extended adjuvant treatment of adults with early-stage HER2-positive breast cancer, after adjuvant trastuzumab-based therapy; treatment, in combination with capecitabine, of advanced or metastatic HER2-positive breast cancer in adults, after ≥2 HER2-targeted regimens in the metastatic setting
Patient support programs